研究人員網頁資料表

姓 名:	歐朔銘	填表日期: (YYYY/MM/DD)	2023/2/19	
單 位:	內科部腎臟科	現職職稱:	主治醫師	
Email:	okokyytt@gmail.com	連絡電話:	28712121 #2995	

學 歷:	陽明交通大學臨床醫學研究所博士
重要經歷:	臺北榮民總醫院內科部腎臟科主治醫師 國立陽明大學醫學系內科學科兼任副教授 臺北榮民總醫院腎臟科總醫師 臺北榮民總醫院內科部住院醫師
研究方向: (關鍵詞)	腎臟免疫學、急性腎臟損傷、腎臟移植學、大數據分析、腎臟基因體學
五年內 **代表**著作:	1. Associations of the Serum Total Carbon Dioxide Level with Long-Term Clinical Outcomes in Sepsis Survivors. Yang CH, Chen YA, Bin PJ, **Ou SM***, Tarng DC*. Infect Dis Ther. 2023 Feb;12(2):687-701. 2. Echocardiographic features of left ventricular dysfunction and outcomes in chronic kidney disease. **Ou SM**, Chao CJ, Tsai MT, Lee KH, Tseng WC, Bin PJ, Lin YP, Hsu CY, Tarng DC. Heart. 2022 Dec 22;109(2):134-142. 3. Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease. Niu CY, Yang SF, **Ou SM**, Wu CH, Huang PH, Hung CL, Lin CC, Li SY.J Am Heart Assoc. 2022 Sep 20;11(18):e026407. 4. Plasma Galectin-9 Is a Useful Biomarker for Predicting Renal Function in Patients Undergoing Native Kidney Biopsy. Tsai MT, Yang RB, **Ou SM**, Tseng WC, Lee KH, Yang CY, Chang FP, Tarng DC. Arch Pathol Lab Med. 2023 Feb 1;147(2):167-176. 5. Urinary Galectin-3 as a Novel Biomarker for the Prediction of Renal Fibrosis and Kidney Disease Progression. **Ou SM**, Tsai MT, Chen HY, Li FA, Lee KH, Tseng WC, Chang FP, Lin YP, Yang RB, Tarng DC. Biomedicines 2022, 10(3), 585 6. Artificial Intelligence for Risk Prediction of End-Stage Renal Disease in Sepsis Survivors with Chronic Kidney Disease. Lee KU, Chu YC, Tsai MT, Tseng WC, Lin YP, **Ou SM***, Tarng DC*. Biomedicines February 2022 10(3):546 9. Sepsis and the Risks of Long-Term Renal Adverse Outcomes in Patients With Chronic Kidney Disease. **Ou SM**, Lee KU, Tsai MT, Tseng WC, Chu YC, Tarng DC. Front. Med., February 2022

五年內 **代表**著作(續)	7. Artificial Intelligence for Risk Prediction of Rehospitalization with Acute Kidney Injury in Sepsis Survivors. **Ou SM**, Lee KH, Tsai MT, Tseng WC, Chu YC, Tarng DC. J Pers Med. 2022 Jan 4;12(1):43. 8. Magnesium exposure increases hip fracture risks in patients with chronic kidney disease: a population-based nested case-control study. Chen YT, Kao ZK, Shih CJ, **Ou SM**, Yang CY, Yang AH, Lee OK, Tarng DC. Osteoporos Int. 2022 Jan 7. 9. Associations of high anti-CMV IgG titer with renal function decline and allograft rejection in kidney transplant patients. Chen TH, **Ou SM***, Tarng DC*. J Chin Med Assoc. 2021 Dec 8. 10. Identification of Galectin-3 as Potential Biomarkers for Renal Fibrosis by RNA-Sequencing and Clinicopathologic Findings of Kidney Biopsy. **Ou SM**, Tsai MT, Chen HY, Li FA, Tseng WC, Lee KH, Chang FP, Lin YP, Yang RB, Tarng DC. Front Med (Lausanne). 2021 Nov 12;8:748225. 11. Antithrombotic Therapy for Chronic Kidney Disease Patients With Concomitant Atrial Fibrillation and Coronary Artery Disease. Lee KH*, **Ou SM***, Chu YC, Lin YP, Tsai MT, Tarng DC. Front Cardiovasc Med. 2021 Oct 8;8:751359. 12. Relationship between Circulating Galectin-3, Systemic Inflammation, and Protein-Energy Wasting in Chronic Hemodialysis Patients. Tsai MT, **Ou SM**, Chen HY, Tseng WC, Lee KH, Yang CY, Yang RB, Tarng DC. Nutrients. 2021 Aug 16;13(8):2803. 13. Associations of atrial fibrillation with renal function decline in patients with chronic kidney disease. Chen TH, Chu YC, **Ou SM***, Tarng DC*. Heart. 2021 Jun 30:heartjnl-2021-319297.
研究室成員:	張緯弘、陳致安